Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

Pharmaceuticals

Noah M. Merin²  Kevin R. Kelly¹ 

[1] Internal Medicine, Jane Anne Nohl Division of Hematology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA; E-Mail

关键词: multiple myeloma;    proteasome inhibitors;    toxicity;   

DOI  :  10.3390/ph8010001

来源: mdpi

【 摘 要 】

Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.